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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the evidence of the eFectiveness of preconception care interventions to improve pregnancy outcomes for women with epilepsy
(WWE). The objectives include:
• A synthesis of quantitative data on the eFectiveness of diFering preconception interventions for improving pregnancy planning and
fitness for pregnancy.
• A synthesis of qualitative data on participants' experiences, opinions and preferences regarding preconception care/counselling.
• A convergent synthesis integrating the results of quantitative and qualitative synthesis to address the overall review question (a results-
based convergent synthesis), to enhance and extend understanding of how preconception care/counselling interventions may work
and how context impacts on the implementation.
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B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological disorder aFecting up to 1%
of the population (Hauser 1990). The incidence of the condition
is linked to social deprivation (Pickrell 2015), and it is estimated
that 75% of people with epilepsy reside in low- and middle-income
countries (LMIC) (Espinosa-Jovel 2018). Active point prevalence
of epilepsy in women is estimated to be 6.85 cases per 1000;
reported incidence rates are thought to be lower in women, due
to concealment of the diagnosis, in counties where women with
epilepsy (WWE) are perceived to be unmarriageable and are socially
marginalised (Fiest 2017).
Antiepileptic drugs are the mainstay of treatment for the majority
of individuals with epilepsy, of whom approximately one-third
of those receiving antiepileptic drugs (AEDs) are women of
reproductive age (Yerby 1994). It is estimated that 0.3% to
0.7% of all births are to women with epilepsy, most of whom
require continuation of AEDs during pregnancy due to the risks
of uncontrolled seizures to the mother and fetus (Joint Epilepsy
Council 2011; Lunardi 2011; Tomson 2011). The estimate of in utero
exposure to AEDs or uncontrolled seizures (or both) is likely to be
higher for WWE in Low-to-Middle Income Countries (LMIC), owing
to the impact of the treatment gap and disease-related stigma on
the care of WWE (von Gaudecker 2017).
Whilst the outcome of pregnancy for the majority of WWE is
normal, the risk of adverse pregnancy outcomes — such as
maternal mortality and morbidity, together with fetal risks of
death, major congenital malformations, dysmorphism (anatomical
malformation) and long-term cognitive delay — is two to three
times higher (Bromley 2017; Weston 2016). The magnitude of fetal
risk is influenced not only by the type of AED (e.g. Increased risk is
associated with the use of the drug, valproate; there is international
consensus that its use should be avoided in pregnancy when
possible (MHRA 2019.)) but also, AED dosage and other variables
(e.g. maternal age and parental history of major congenital
malformation), all of which need to be taken into account in
the management of epilepsy in women of childbearing potential
(Tomson 2011). Geographical variations for epilepsy care provision
have been shown to increase the risk of pregnancy complications,
including risks of sudden unexpected death in epilepsy (SUDEP)
and poorer pregnancy outcomes for WWE in LMIC and resource-
poor settings (Allotey 2017; Edey 2014; Galappatthy 2018).
Description of the intervention
Preconception care is defined by the World Health Organization as
a series of promotive, preventive and curative health interventions
able to benefit a wide range of stakeholder needs to maximise
the gains for maternal and child healthcare (WHO 2013).
Preconception interventions include those interventions with
the intention of improving maternal and child health prior to
conception in a woman of childbearing potential. This includes
the stages of preparation for a first pregnancy and peri-conception
interventions to improve future outcomes by intervening in
between pregnancies (PHE 2018a). Preconception interventions
involve single or multiple health risk assessments, education and
counselling (delivered as a single session or an intense programme
involving multiple sessions over several weeks) (Hussein 2016).
The eFectiveness of preconception care interventions relies on the
identification of and reduction in (modifiable) risk factors before
conception in order to improve obstetric outcomes (Steegers 2005).
Preconception interventions employ both individual and
population perspectives to improve health before pregnancy
(by planning for pregnancy, e.g. use of contraception to
avoid pregnancy until the right time) and improve fitness
for pregnancy (e.g. risk assessment/health promotion/health
behavioural interventions), with the benefit of improved outcomes
for mothers and babies (PHE 2018a). The settings for preconception
intervention delivery include primary and secondary healthcare;
social care, education, religion and community providers including
public health initiatives (e.g. family planning); and the voluntary
sectors (PHE 2018a; WHO 2013).
The International League Against Epilepsy Women and Pregnancy
Task Force have recommended management strategies/discussion
topics, blood tests, and communication between professionals
and the patient (Tomson 2019b). Preconception management for
WWE includes the following: risk assessment, health education and
promotion, and targeted advice concerning epilepsy.
Risk assessment
Risk assessment involves the identification and quantification of
modifiable health risks associated with antiepileptic medication
and seizures prior to pregnancy. All older AEDs and the majority
of the newer AEDs are classed as teratogenic agents with the
potential to influence structural congenital anomalies, growth
disturbance, and functional deficits such as behavioural and
cognitive abnormalities, that may not be apparent until some
time aMer birth (Friedman 2013). Valproate should be avoided
whenever possible; and where possible monotherapy or AED
withdrawal should be considered, whilst balancing the risk of
seizure against the risks associated with AED use (Tomson 2019b).
A risk assessment will involve identification of WWE at risk of poor
adherence to AED treatment, and those at risk of abrupt withdrawal
of AEDs on the discovery of pregnancy. The identification of risk will
support targeted advice concerning epilepsy, for example warning
against abrupt AED withdrawal on the discovery of pregnancy as
a contributing factor  to uncontrolled epilepsy during pregnancy
and risk of sudden unexpected death in epilepsy (SUDEP).
Guidelines recommend communication of risk information that
emphasises the importance of optimising and maintaining AEDs
during pregnancy (McCall 2018; RCOG 2016).
Health education and promotion
Health education and health promotion interventions target
behaviours to improve fitness for pregnancy, including promoting
knowledge of (and initiation of) vitamin D and folic acid,
immunisation, reducing alcohol, giving up smoking, contraception
and family spacing, and sexual health (PHE 2018b; Whitworth 2009).
Health promotion activities aim to improve health knowledge and
awareness in advance of sexual activity, and focus on pregnancy
planning to avoid pregnancy until the time of optimal health
(Hanson 2015); this also includes pre-pregnancy seizure control
(Tomson 2019b). Contraceptive advice for WWE promotes the
selection, and use, of appropriate contraception and promoting
awareness of the clinically significant interactions between AEDs
and contraceptive drugs (De Weerd 2002; Pack 2009; SIGN 2019).
Promoting preconception healthcare in adolescence, at a life
stage when many behaviour patterns become established, is a
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key recommendation made by the UK Chief Medical OFicer (PHE
2018b). This is a further challenge for adolescents with epilepsy
since WWE experience earlier sexual debut compared to their non-
epilepsy population controls (Lossius 2016).
Targeted advice concerning epilepsy
Women and girls with epilepsy require information and counselling
to be tailored to their personal needs, on topics including:
contraception, conception, pregnancy, caring for children and
breastfeeding. This information/counselling needs to be provided
in advance of sexual activity and pregnancy (NICE 2012; SIGN 2019).
Due to the risk of unplanned pregnancy, women taking AEDs are
recommended to take a high-dose folic acid supplement (5 mg/
day) (NICE 2012; RCOG 2016; Tomson 2019b).
Due to the chronic nature of epilepsy, targeted preconception care
requires an ongoing process of preparation and review of epilepsy
management, to ensure the WWE conceives with a minimum of
risk factors, is fully aware of any risks and benefits of treatment,
and is able to make informed decisions about future pregnancies
(Crawford 2005).
How the intervention might work
Preconception care interventions bring together an interventional
process involving assessment, planning, treatment, education,
decision support and counselling, resulting in a wide range of
potential health outcomes before, during and aMer pregnancy
for both the woman and her future oFspring (NICE 2019).
  Preconception care is conceptualised through a life course
approach and takes account of intervening to improve fitness
for pregnancy by focusing on the "four Ps": pregnancy planning,
pregnancy prevention, pregnancy preparation and preparing for
parenthood (Hanson 2015; PHE 2018b). Programme theory and
the influence of behaviour change communication has been
proposed to support changes in micronutrient interventions
for population health outcomes (Centeno Tablante 2019; WHO
2016). Social cognitive theory has been proposed to support
the development and maintenance of reproductive/preconception
health behaviours (Winterbottom 2012). See Figure 1.
 
Figure 1.   AED: antiepileptic drug
WWE: women with epilepsy
Logic model adapted with reference to WHO/CDC (2016), Tablante (2019), PHE (2018) and Winterbottom (2012).
 
Improving rates of a planned pregnancy for WWE will result
in more women having preconception epilepsy reviews and
appropriate changes in prescribing (Leach 2017). Making changes
from treatment with high-risk AEDs has the potential to prevent
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31 children each year born to mothers with epilepsy being
aFected by major congenital malformation, with an estimated
cost saving of GBP 1,746,000 (in 2011) by avoiding valproate
alone, and reducing the economic burden by preventing five
cases of spina bifida per year (Kinney 2011). The European
Epilepsy and Pregnancy register have reported a 27% reduction
in rates of AED-related major congenital malformations since 2000
due to changes in prescribing (reducing use of valproate and
carbamazepine), without significant changes to rates of tonic-
clonic seizures in pregnancy over the same time period (Tomson
2019a). Additional strategies to reduce valproate exposure have
been implemented, including mandatory risk acknowledgement
and pregnancy prevention, further demonstrating the importance
of planning pregnancy and having epilepsy reviews to optimise
AEDs and seizure control before conception (EMA 2018; MHRA
2019).
Pre-pregnancy commencement of folic acid supplementation has
been proposed to influence the neurodevelopmental outcomes of
children born to mothers with epilepsy (Meador 2011). Improving
the provision of risk information ahead of pregnancy is proposed
to reduce the risk of adverse pregnancy outcomes, by supporting
the completion of AED changes prior to pregnancy, thereby
reducing the rates of abrupt withdrawal of AED or termination
of an otherwise wanted pregnancy (Betts 1999; Rapcencu 2012).
The changes to prescribing patterns observed in the European
Epilepsy and Pregnancy register (EURAP) revealed a significant
27% decrease in the prevalence of major congenital malformations
(Tomson 2019a).
Why it is important to do this review
This review will address the increased focus on the benefits
of preconception care (WHO 2013), as a complex intervention
to improve reproductive health (PHE 2018b). The need for this
updated review was confirmed in an online patient and public
involvement survey managed by one UK voluntary organization,
Epilepsy Action, which highlighted the need to include core
outcomes of relevance to WWE and their key supporters. This
review will seek to increase understanding of the importance  of
pre-pregnancy interventions to improve  maternal neurological
outcomes prior to pregnancy, and the potential to influence
obstetric and oFspring outcomes (Al Watter 2017).
This updated review protocol will extend the scope of the
original review (Winterbottom 2008), to evaluate quantitative and
qualitative research to improve understanding, and strengthen
and extend the evidence of the eFectiveness of preconception
interventions for WWE. It will also take into account all of the key
stakeholder perspectives.
The rationale for this review is in response to the following key
recommendations.
• To reduce preventable maternal death among pregnant and
postpartum WWE (Kelso 2017; Knight 2014).
• To improve risk assessment and communication about high-risk
AEDs, including valproate, for women of childbearing age (EMA
2018; Kmietowicz 2016; MHRA 2019).
• To improve maternal and child health outcomes by intervening
to improve preconception health (PHE 2018a).
O B J E C T I V E S
To assess the evidence of the eFectiveness of preconception care
interventions to improve pregnancy outcomes for women with
epilepsy (WWE). The objectives include:
• A synthesis of quantitative data on the eFectiveness of diFering
preconception interventions for improving pregnancy planning
and fitness for pregnancy.
• A synthesis of qualitative data on participants' experiences,
opinions and preferences regarding preconception care/
counselling.
• A convergent synthesis integrating the results of quantitative
and qualitative synthesis to address the overall review
question (a results-based convergent synthesis), to enhance and
extend understanding of how preconception care/counselling
interventions may work and how context impacts on the
implementation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Quantitative studies
• Randomised controlled trials. These studies will be considered
if individual or cluster-randomised allocation were used.
• Quasi-randomised trials (with the exclusion of cross-over trials
as this design is not feasible for the intervention).
• Non-randomised studies. These studies will be considered for
inclusion if they used study design descriptors as suggested
within the Cochrane Handbook for Systematic Reviews of
Interventions (Reeves 2019). Justification for inclusion of non-
randomised studies is based on the results of the original review
and as an update extending to include mixed-methods; the
protocol authors recognise the potential diFiculty in conducting
randomised studies in this topic as prospective participants will
likely have a strong reason for the preference for the intervention
and restriction/delay of the intervention delivery would be
unethical (Reeves 2019).
Qualitative studies
Qualitative studies will be considered for inclusion if they used
qualitative methods for data collection (e.g. focus group interviews,
individual interviews, observation, document analysis, experiential
and interpretative studies) and also qualitative methods for data
analysis (e.g. grounded theory, interpretative phenomenological
analysis, discourse analysis, thematic analysis). This criterion has
been successfully used as a basic quality threshold for considering
studies for inclusion, thereby excluding studies where qualitative
methods were used to gather data that were then analysed using
descriptive statistics (Ames 2017).
Qualitative studies reporting the views and opinions of participants
of preconception care programmes will be considered if they used
qualitative methods of data collection and data analysis reporting
people's perspectives, beliefs, feelings, understanding, experiences
or behaviour that were presented as data (e.g. direct quotes from
participants or description of findings). There will be no limits on
location, however, the language will be limited to English due to the
cost requirements of detailed and specialist language translation.
Preconception care for women with epilepsy: a mixed methods review (Protocol)
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Types of participants
Quantitative studies
Participants of interest are women of childbearing potential
aged 12 to 50 years, with a confirmed diagnosis of epilepsy,
who are on or oF treatment. Due to ethical concerns of
withholding interventions, controlled trials will be considered
with a comparison between diFering interventional components,
delivery methods or healthcare settings.
Participants of interest in cluster-RCTs will be "those on whom the
investigators seek to measure the outcome of interest" (Higgins
2019c). How individual participants are identified and recruited
within clusters will be noted.
In addition, studies will be considered taking account of women
and their spouse/partners, carers, other family members, or
members of the health and social care team, and the voluntary
sector.
Qualitative studies
We will include women of childbearing potential aged 12 to
50 years, with a confirmed diagnosis of epilepsy, who have
experienced preconception care or who have expressed an
interest in preparing for pregnancy. WWE who have experience of
unplanned pregnancy, who failed to attend preconception care,
may also be included. Participants may also be extended to include
people with epilepsy, partners, carers or other family members of a
person with epilepsy, members of the health and social care team,
and the voluntary sector.
Types of interventions
Preconception care interventions include any educational, health
promotion, or counselling interventions (or a combination of these)
targeting WWE, with the intention of improving preconception
health outcomes. These interventions are delivered in hospitals or
the community. Programmes could vary in content (e.g. changes
of AED; provision of risk information; commencement of folic acid)
and their delivery mode (individual (hospital or community clinic)
or group (hospital or community)), length, frequency or intensity
(see Subgroup analysis and investigation of heterogeneity).
Interventions, such as valproate risk acknowledgement/pregnancy
prevention programmes (required annually in the UK) may be
oFered before the decision to have a baby, and acknowledge
the return for an earlier review if there are changes in plans for
pregnancy (MHRA 2019).
We will include pre-pregnancy and between-pregnancy
interventions involving assessment of lifestyle, health and fitness
by a healthcare professional (NICE 2019). Preconception care
interventions will also be considered for inclusion if the
interventions include any of the following: epilepsy review with
the intention of reducing the number or dose of AEDs or reducing
seizure-related risk; improving the chances of healthy pregnancy
outcome through health improvement and health education
including risk information; improving knowledge of the importance
of planned pregnancy; avoiding unplanned pregnancy and
increasing uptake of contraception; knowledge of contraception
and potential AED-related interactions; interventions focused on
improving preconception care uptake and adherence).
Control groups (if present in the study design) might include
a comparison of diFerent intervention components or delivery
methods.
Studies will be considered for inclusion if they explore
preconception care (including the delivery of care) from the
perspective of the WWE, their partner, family,  members of the
health and social care team, and voluntary sector (see Types of
participants; Types of outcome measures).
Types of outcome measures
As a mixed-methods review, the outcomes of interest are the
improvement in maternal health, including seizure control and
epilepsy management (AED use) prior to pregnancy.
Short/mid-term outcomes, will include the planned pregnancy,
or  pregnancy avoidance during the interventional stages to
improve seizure control and epilepsy management.
Long-term outcomes  will include improvement in obstetric and




• Overall clinical improvement in seizure management prior to
pregnancy
* The proportion of women who are  seizure-free at the
completion of the intervention compared to baseline
* The proportion of women with a reduced seizure frequency
compared to baseline
* The proportion of women who are on monotherapy/
polytherapy (compared pre- and post-intervention)
* The proportion taking valproate  monotherapy/
polytherapy (compared pre-and post-intervention)
• Measures of self-eFicacy and self-management, using validated
scales
• Intention to plan pregnancy, measured by use of validated
scales such as the London Measure of Unplanned Pregnancy
(Hall 2017; PHE 2018b); questionnaires of self-rated pregnancy
intention; use of long-acting reversible contraception (self-
reported, case note review); recorded attendance at
preconception review
• Commencement of folic acid (self-reported, case note review)
• Knowledge of preconception care and epilepsy in pregnancy
issues, measured by questionnaire pre- and post-intervention;
and/or, measured by validated epilepsy in pregnancy
knowledge scale; epilepsy knowledge scale; preconception
health/reproductive health scale
• Serious adverse events (mortality, SUDEP, seizure-related injury,
pregnancy exposed to valproate)
• Adverse events relating to the intervention, measured as the
proportion of individuals experiencing any of the following
adverse eFects: anxiety (measured by a validated scale, e.g.
the Hospital Anxiety  and Depression  Scale  (HADS), pre- post-
intervention); unplanned pregnancy; accidental pregnancy (as
defined by study authors, measured yes/no); the proportion of
unplanned pregnancy associated with AED polytherapy
Preconception care for women with epilepsy: a mixed methods review (Protocol)
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Pregnancy outcomes
Whilst pregnancy outcomes are important primary outcomes, it is
recognised that pregnancy might not be an appropriate outcome of
all recipients of preconception care interventions, especially where
the primary outcome of the intervention is pregnancy prevention
for WWE taking a high-risk AED(s), and pregnancy prevention
recommended during the planned switch of AED(s). Medium/long-
term preconception care intervention outcomes are seen as the
primary prevention of adverse pregnancy outcomes.
The following outcomes will be reviewed, if available when
considering studies for inclusion.
• The proportion of women who maintain pre-pregnancy seizure
control in pregnancy.
• Obstetric outcomes, measured by booking early into antenatal/
prenatal review (i.e. weeks of gestation at booking); obstetric
complications (Al Watter 2017); live birth; miscarriage; stillbirth;
preterm birth; mode of delivery; breastfeeding (yes/no;
measured by the number of weeks/months).
• Congenital malformations, measured by rates and frequency of
classified abnormality.
• Neurodevelopmental outcomes, measured by a validated scale
of infant development e.g. Bayley Scales of Infant and Toddler
Development (Bromley 2017).
• Registration with the Epilepsy in Pregnancy Register (yes/no).
• Infant/maternal mortality and morbidity.
The qualitative phenomenon of interest
The phenomenon of interest for qualitative studies will include the
perceptions and experiences of WWE, their partners, friends, family,
healthcare providers and other key stakeholders. Qualitative
studies will be considered for inclusion if reporting opinions
and experiences of preconception care/counselling from any
stakeholder perspective (e.g. views and beliefs about the utility
of pregnancy planning to improve preconception health for
WWE; barriers to adherence to preconception care interventions;
observations and experiential accounts).
Secondary outcomes
Quantitative outcomes
• Adherence to the intervention (i.e. retention rate, characteristics
of non-responders)
• Knowledge of AED-related contraceptive interactions, and
alternative eFective contraceptive methods, measured by
questionnaire/self-report (pre- and post-intervention)
• Adherence to AEDs (AED adherence, measured by self-report,
hair analysis, AED blood level monitoring, or use of adherence
technology; validated drug-adherence measure)
• Pre-conception health improvement: smoking/alcohol
cessation, weight management; measured by validated rating
scales, questionnaire, self-report (pre- and post-intervention)
(Whitworth 2009)
• Measures of quality of life, using validated scales for people with
epilepsy
• Satisfaction with care, including involvement in shared
decision-making, measured by a validated rating scale, or as
defined by the study authors
• Breastfeeding (yes/no)
• Infant and child injury  secondary to maternal seizures (self-
reported, questionnaire)
Outcomes will be considered in selecting studies for inclusion;
however, it is acknowledged that studies are unlikely to report on
all outcomes of interest. We intend to include studies reporting
on at least one or more outcomes of interest, with time frames of
measurement of outcomes considered for inclusion pre-specified
as 'short-term' or 'medium/long term', as referred within the logic
model (see Figure 1).
Search methods for identification of studies
The search methods for this mixed-methods protocol have been
updated and extended to include additional criteria, with the
goal of retrieving both non-randomised studies and qualitative
studies, as suggested in Cochrane Handbook (Higgins 2019a; Noyes
2019a). The search methods for qualitative research were informed
by running and re-running selected search terms in a simulated
review in order to address the challenges of identifying studies
by title and to counter inadequate indexing and other factors
as barriers (Booth 2016a). The challenge of searching for both
quantitative and qualitative research in this mixed methods review
will be acknowledged and documented in suFicient detail to
allow full reporting in the complete review (search terms used,
additional sources of evidence retrieval used, number of hits).
For quantitative research, a systematic and thorough search of all
available evidence is required and will be presented. The retrieval
of qualitative research using the same strategies as quantitative
research has been reported as diFicult and ineFective (Booth
2016a). Locating qualitative research requires an iterative process
searching for data able to reflect the review objectives; this will
include contacting authors of quantitative research to ask for
details of qualitative add-on studies or stand-alone studies. Full
details of the search strategy/processes for the identification of
qualitative studies will be reported.
Electronic searches
We will search the following databases.
• The Cochrane Epilepsy Group’s Specialised Register and the
Cochrane Central Register of Controlled Trials (CENTRAL), via
the Cochrane Register of Studies (CRS Web), using the search
strategy set out in Appendix 1.
• MEDLINE (Ovid) 1946 to present, using the search strategy set
out in Appendix 2.
• SCOPUS 1823 to present, using the search strategy set out in
Appendix 3.
• CINAHL Plus (EBSCOhost) 1937 to present, using the search
strategy set out in Appendix 4.
• PsycINFO (EBSCOhost) 1887 to present, using the search
strategy set out in Appendix 5.
• ClinicalTrials.gov, to present, using the search terms:
Preconception counselling OR Preconception care | Epilepsy.
• WHO International Clinical Trials Registry Platform ICTRP, to
present, using the search terms: Preconception counselling AND
epilepsy OR Preconception care AND Epilepsy.
No restrictions will be placed on the date of publication. The
language will be restricted for qualitative studies due to the costs
associated with detailed and specialist translation.
Preconception care for women with epilepsy: a mixed methods review (Protocol)
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Searching other resources
We will search conference abstracts for the last five years (2015 to
2020) from conferences including: International Epilepsy Congress,
European Congress on Epileptology and American Epilepsy Society
Meeting.
Reference lists of original research and review articles will be cross-
matched to the studies generated from the electronic searches.
Reference lists of recent review articles will be searched and lead
corresponding authors in the area will be contacted for any relevant
unpublished material. Citation searching and contact with experts
in the area will be used to overcome problems with indexing of
qualitative studies (Booth 2016a).
Data collection and analysis
We will apply inclusion and exclusion criteria and report any
deviation from the protocol. We will firstly complete analysis of
included quantitative studies, then complete the second analysis
of included qualitative studies. We will then complete a final mixed
method analysis combining both quantitative and qualitative data.
Selection of studies
Two review authors (JW and AM) will independently apply inclusion
and exclusion criteria successively to titles, abstracts and full
reports. Full details of possibly relevant studies will be obtained and
assessed independently for inclusion in the review. Multiple reports
of the same study will be linked together. If necessary, authors will
be contacted to clarify study eligibility. If a disagreement occurs,
the review authors will attempt to reach a consensus by discussion
or involvement of a third author (CTS to resolve disagreement for
the selection of quantitative studies; AN to resolve disagreement for
the selection of qualitative studies; and AGM for any disagreement
concerning eligibility).
We will list all studies excluded aMer full-text assessment and the
reasons for exclusion in the 'Characteristics of excluded studies'
section. We will document the study selection process in a flow
chart, as recommended in the PRISMA statement (Moher 2009),
and will show the total numbers of retrieved references and the
numbers of included and excluded studies (and reasons why they
were excluded).
Studies that do not meet the inclusion criteria will be excluded
and their bibliographic details listed, with reasons for exclusion. For
studies published in abstract form only, we will include the study if
it is clearly eligible; if this is unclear then we will contact the study
authors for further information and place the study in the 'Studies
awaiting classification' section of the review until a reply is received
(in an appropriate time frame).
Selecting quantitative studies for inclusion
If both randomised and non-randomised trials are defined eligible
for an intervention addressing a specific outcome, then we will
follow the guidance provided in the Cochrane Handbook for
including non-randomised studies on intervention eFects (Reeves
2019). We plan to present and analyse the results from randomised
and non-randomised trials separately (Reeves 2019).
Qualitative study sampling
When selecting qualitative studies, we will consider the relevance
of an included study to address the review question and meet the
inclusion criteria. We will make an assessment of the relevance
of the included study sample, as this may require the inclusion
of studies that only partially address the context of the review
question, or only cover a subgroup of the population or the subtype
of the intervention stage (Noyes 2018a; Noyes 2019b). The potential
for collecting a large sample of relevant studies will be addressed
by using a sampling frame, with the aim of generating a variation
of concepts rather than an exhaustive sample (Booth 2016a). A
sampling frame will help manage the potential for inclusion of large
numbers of studies and reduce the risk of impairing the quality of
the analysis; we will purposively sample from studies meeting the
review inclusion criteria.
We will use the sampling frame to select qualitative studies based
on closeness to the following criteria:
• Focus on preconception care/counselling.
• The closeness of study data to review objectives.
• The richness of data to address the above criteria.
• Diverse settings.
Judgements on the relevance of the studies selected for
inclusion will be assessed within the GRADE-CERQual (Confidence
in the Evidence from Reviews of Qualitative research) approach to
determine the extent to which the review findings are a reasonable
representation of the phenomenon of interest (Noyes 2019b).
We will list all qualitative studies not included in the purposive
sample, and the reasons for their exclusion, in the 'Characteristics
of excluded studies' section.
Data extraction and management
Use of the PROGRESS (place of residence, race/ethnicity/
culture/language, occupation, gender/sex, religion, education,
socioeconomic status, and social capital) framework will ensure
that all data extraction maintains an explicit equity focus (O'Neill
2014). Two review authors (JW, CTS) will extract quantitative data;
and two review authors (JW, AM) will extract qualitative data, using
a predefined data extraction form. For quantitative studies,  we
will use the  Excel spreadsheet  tool available from  the website
of version 2 of the Cochrane 'Risk of bias' tool for randomised
trials (RoB 2) (RoB2 tools). Any disagreements will be resolved
by discussion with a third review author (AGM for quantitative
studies; and AN for qualitative studies). Data extraction forms will
be piloted by one review author (JW) on at least one quantitative
and one qualitative study. The data extracted will be reviewed for
completeness of required data retrieval (any modifications will be
fully reported in the complete review). Covidence soMware will be
used for importing and de-duplicating citations; screening of titles,
abstracts and full-text reports; and extracting data into excel format
(Covidence). When necessary data are unavailable from the study
report, we will correspond with the study authors.
Quantitative studies
The quantitative data extraction forms will comply with criteria
provided in the Cochrane Handbook (Higgins 2019b) and with
reference to the Cochrane EFective Practice and Organisation of
Care (EPOC) group (EPOC 2017b) and RoB 2 website (RoB2 tools).
Preconception care for women with epilepsy: a mixed methods review (Protocol)









Cochrane Database of Systematic Reviews
The additional requirements for data extraction of non-randomised
study designs will be included (Reeves 2019).
Two review authors (JW, CTS) will obtain the following information
for each included quantitative study, where possible.
Methodology/trial design
1. General information: author, year of publication, journal,
country, and language
2. The number of eligible participants, number randomised if an
RCT, and reasons why patients were not included in the study
3. The number of participants evaluated at follow-up(s) and what
the follow-up time points were
4. Study design features, for example, whether it is an RCT
on masking, whether a  parallel design was used, features of
randomisation, and sample size calculation
5. Description of the content of preconception intervention,
including dosage, duration and method of delivery, number of
sessions/intensity
6. Comparison intervention, including duration and mode
7. Outcome data at all time points, including how they were
measured, and the mean or categorical scores of the primary
and secondary outcomes
8. Notes: funding for the trial, notable conflicts of interest of trial
authors, ethical approval
Participant demographics
1. Age (overall and by treatment group)
2. Gender (preconception care is increasingly targeting women
and their partners)
3. Epilepsy/seizure type
4. Epilepsy duration and aetiology
5. Existing antiepileptic drug regimen (including dose, overall and
by treatment group)
6. Baseline seizure frequency (overall and by treatment group)
7. Co-morbidity, including pregnancy history
8. Type of health care or community setting,
9. Stage of pregnancy intention and/or patient factors determining
the selection of the type of intervention considered, and reasons
given for the selection of preconception care intervention
Outcome data
We will extract from each included study the number of participants
who met the following criteria:
1. Number of women included in the analysis of each outcome by
the intervention group.
2. Outcome summary of data for each intervention (see Types of
outcome measures).
For all serious adverse events, and adverse event reporting, we will
extract data on both intervention and control/comparison arms. We
will record any intervention withdrawal (e.g. withdrawal aMer the
first visit), the number of serious adverse events, and the adverse
events per intervention arm/period.
For continuous outcomes, we will extract the means and standard
deviation of the comparison groups, where possible. 
We will extract the study authors' definitions of the duration of
seizure freedom; planned pregnancy and preconception folic acid
intake, and important outcomes included in the review. We will
extract the measure  used in  included studies to measure the
reported outcome. We will extract arm-level data were possible,
and if not available we will extract eFect size. We will extract data
at the authors' defined time points.
Data on potential eBect modifiers
We will extract data on the following potential eFect modifiers from
each included study:
• Population: seizure frequency at baseline; the number of AEDs
at baseline; and the number taking valproate at baseline.
• Study design: follow-up duration.
• Intervention: intensity, for example, single visit; the number of
intervention visits; the time between visits.
Specifically for non-randomised studies, we will follow the
guidance in the Cochrane Handbook (Reeves 2019). Where possible,
we will also extract the following.
• Data on confounding factors considered and methods used to
control for confounding. We will use the ROBINS-I tool as a
template for this information (Sterne 2019a).
• Comparability of groups on confounding factors considered.
• Data about multiple eFect estimates (both unadjusted and
adjusted estimates, if available).
• Outcome data; including the type of outcome, how measured,
and time point for primary and secondary outcomes.
• Study design characteristics: for example, whether there was
a comparison, participant/cluster allocation, which parts of
the study were prospective, which variables were assessed for
comparability between groups.
Qualitative studies
We will enter data into QSR NVivo 11 qualitative electronic analysis
soMware to support analysis (NVIVO11). We will use data extraction
methods to preserve the context of the primary study data,
to extract detailed contextual and methodological information
on each study, and to report this information in a table of
‘Characteristics of included studies’ (Noyes 2019a).
The following information will be extracted for each qualitative
study, independently by two review authors (JW, AM).
• Methodology/study design
* Qualitative methodology (e.g. grounded theory,
ethnography, etc.)
* Study location and settings
* Study aims
* Method of collecting data (e.g. observation/focus groups/
interviews, etc.)
* Method of analysis (e.g. thematic/discourse analysis, etc.)
* Method of sampling (e.g. stratified, purposeful, etc.)
* Source of funding
* Quality assessment (Critical Appraisal Skills Programme
(CASP) tool; Appendix 6)
* Source of funding
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• Participants/demographics
* Number of participants




• Findings (the findings of interest can be located anywhere
in a qualitative paper, and can be presented in a variety of
formats, including text quotes, themes, conceptual framework
and typologies, theories, charts, models and diagrams, photos
and images, and also as supplementary online data). In order to
take these factors into consideration, the data extraction form
will be flexible, including the following.
* Quotes, pictures, photographs, images.
* Themes, conceptual frameworks or theories, diagrams,
charts, typologies.
* Views and interpretation relating to the delivery,
communication, and/or perceived eFectiveness of the
preconception intervention.
* Evidence of interest in any format, or reported within any
section of the included paper, and/or additional online-only
files.
Assessment of risk of bias in included studies
Assessment of risk of bias will be conducted for all studies meeting
the inclusion criteria, using accepted methods for included study
designs (randomised, non-randomised, and qualitative) (Sterne
2014; Sterne 2019a; Sterne 2019b; Noyes 2019a).
Quantitative studies
Assessment of risk of bias for included randomised controlled trials
Two review authors (JW and CTS) will independently assess the risk
of bias for each included study using the RoB 2 tools as outlined in
the Cochrane Handbook (Higgins 2019b). We will follow the interim
guidance from the RoB 2 team for assessment of cluster-RCTs
(Sterne 2019b, RoB2 tools).  If there is disagreement in assessment,
a third review author (AGM) will be consulted and a consensus
judgement recorded.
We will use the RoB 2 tool to assess the following domains
(for cluster-RCTs, additional signalling questions will be used for
Domain 1b, in accordance with the interim guidance from the RoB
2 team).
• Domain 1: risk of bias arising from the randomisation process.
• Domain 1b: risk of bias arising from the timing of identification
and recruitment of participants (for cluster-RCTs).
• Domain 2: risk of bias due to deviations from the intended
interventions (eFect of assignment to intervention).
• Domain 3: risk of bias due to missing outcome data.
• Domain 4: risk of bias in the measurement of the outcome.
• Domain 5: risk of bias in the selection of the reported results.
A judgement will be made for each domain, in response to a series
of signalling questions.  We will determine the overall risk of bias
of each included outcome; this will be judged as 'low' if the risk of
bias is low for all domains. The risk of bias will be judged as 'some
concerns' if at least one domain is 'low', but not at high risk for any
domain. The risk of bias will be judged 'high' if there is a high risk of
bias in at least one domain or some concerns for multiple domains
in a way that substantially lowers confidence in the result (Higgins
2019b). Justification of the responses will be included in the free
text box, and the option to predict (and explain) the likely direction
of bias will be applied as appropriate (Higgins 2019b).
The overall risk of bias will be assessed to form a judgement of
predicted direction of bias for the outcome (either: 'not applicable',
'favours experimental', 'favours comparator', 'towards null', 'away
from null' or 'unpredictable'). The overall RoB 2 judgement for each
result will be used to contribute to the GRADE assessment for each
result.
We will focus on the review outcomes and on the nature of the
eFect of intention-to-treat, to support final judgements and assist
in drawing conclusions about preconception care for WWE.  We
intend to review results by means of the type of outcome, how
the outcome was measured, and at which time points results were
reported.
Assessment of risk of bias for included non-randomised studies of
interventions
For non-randomised studies of interventions (NRSI), we will use
the ROBINS-I tool for evaluating the risk of bias in estimates of
the comparative eFectiveness (harm or benefit) of interventions
from studies that did not use randomisation to allocate units
(individuals or clusters of individuals) to comparison groups (Sterne
2019a). Two review authors (CTS, JW) will independently follow
the ROBINS-I methods to assess the risks of bias covering seven
domains; pre-intervention, at intervention, and post-intervention
(Sterne 2016a).
• Pre-intervention
* Domain 1: Bias due to confounding
* Domain 2: Bias in the selection of participants into the study
• At intervention
* Domain 3: Bias in the classification of interventions
• Post-intervention
* Domain 4: Bias due to deviations from intended interventions
* Domain 5: Bias due to missing data
* Domain 6: Bias in the measurement of outcomes
* Domain 7: Bias in the selection of the reported result
The assessment of the risk of bias for each domain will be based
on answers to the ROBINS-I signalling questions. If answering no to
the signalling questions for a domain having potential problems,
then the risk of bias for the domain can be judged to be low
(Sterne 2016a). The categories for risk of bias judgements are “Low
risk”, “Moderate risk”, “Serious risk” and “Critical risk” of bias.  The
results will be used to formulate an overall judgement on the risk
of bias for the outcome and result being assessed. We will follow
the full guidance documentation for  ROBINS-I  and comply with
the latest variants for diFerent included study designs (ROBINS-I).
The ROBINS-I assessment requires consideration of the problems
that might arise in the context of the research question, and when
making a causal assessment of the eFect of the intervention(s)
of interest on the basis of NRSI (Sterne 2016a). In line with
ROBINS-I methods, at the protocol stage, consideration of potential
confounding domains and co-interventions was addressed. (Sterne
2019a).
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Confounding domains
• Seizure severity
• Presence of co-morbidity (e.g. diabetes, mental disorders)
• Healthcare use (e.g. patient in receipt of specialist epilepsy care
versus primary care; or no healthcare use versus healthcare use
in the preceding 12 months)










Evaluations of the risk of bias in an NRSI is conceptualised as the
attempt to emulate a pragmatic randomised trial,  referred to as
the target trial. The first part of a ROBINS-I assessment for a
particular study is to specify a target trial. The target trial is a
hypothetical randomised trial to produce  results to be the same
as those from the NRSI under consideration, in the absence of
bias. The key characteristics are the types of participant (including
exclusion/inclusion criteria) and a description of the experimental
and comparator interventions. For each included NRSI, we will
specify a target trail (Sterne 2016b).
We will present a 'Risk of bias' table for all results for all  review
primary outcomes, and all outcomes reported in the 'Summary of
findings' table.
Assessing methodological strengths and limitations of
qualitative studies
We will use the CASP checklist (CASP 2018) to assess the risk of
bias of qualitative views' studies. Two review authors (JW and
AM) will independently apply the CASP tool to determine the
rigour of qualitative methods of included studies. Disagreements
will be resolved by seeking a third review author's view (AN).
The CASP tool will be used to examine the quality of a study in
relation to 10 questions about research aims, appropriateness of
methodology and design, recruitment strategy, data collection,
the relationship of the researcher, consideration of ethical issues,
data analysis, statement of finding and the value of the research
(Noyes 2019b) (see also Appendix 6). We will include a further
criterion to assess methodological rigour to supplement the CASP
checklist by questioning 'usefulness', i.e. how well the intervention
processes were described and whether or not the process data
could illuminate why or how the interventions worked or did not
work (Noyes 2019a).
We will report our assessment of methodological limitations for
each study in the ‘Characteristics of included studies' tables. We
will assess the risk of bias aMer the identification of relevant data
when making judgements about the relative strength of messages
in the included research. We will present a 'Risk of bias' table for all
studies.
Storage and presentation of data
It is anticipated a large volume of data will be generated from the
completion of RoB 2, ROBINS-I and the qualitative analysis. We plan
to make data available in an online format and provide detailed
appendices.
Measures of treatment eBect
When considering treatment eFects, we will take into account the
risks of bias and methodological limitations for the studies that
contribute to that outcome.
Quantitative studies
When at least two studies are available for comparison with
the same outcomes, we plan to present dichotomous data as a
risk ratio (RR) with 95% confidence intervals (CIs) (e.g. for the
outcomes preconception commencement of folic acid, pregnancy,
and registration into the UK Epilepsy and Pregnancy Register). We
will adjust for baseline diFerences, in line with EPOC and Cochrane
methodology (EPOC 2017a; Higgins 2019a).
For continuous data, we plan to present the overall eFect
estimates as mean diFerences or standardised mean diFerences
(SMDs) depending on the nature of the measures being used.
For continuous outcomes measured on the same scale (e.g. the
Liverpool Seizure Severity Scale or London Measure of Unplanned
Pregnancy) we will estimate the treatment eFect using mean
diFerences and 95% CIs. For continuous outcomes that measure
the same underlying concepts (e.g. preconception knowledge,
attitudes, behaviour change) but use diFerent measurement
scales, we will calculate the SMD. We plan to express time-to-
event data as hazards ratio (HR) with 95% CIs. We will present
conceptually distinct outcomes in separate forest plots.
If it is possible to combine continuous outcomes (such as cognitive
eFects and quality of life) in a meta-analysis, we plan to report the
mean diFerence. However, since we expect to identify significant
variability, we plan to report the SMD. In the event that there
is significant clinical heterogeneity (determined as variability in
the participants, interventions and outcomes studied) of outcome
measures, and meta-analysis is deemed to be inappropriate, we
plan to report the results of these outcomes narratively.
Specific issues for non-randomised studies of interventions
We will take into account EPOC methodology when analysing
results from interrupted time series (ITS) study designs (EPOC
2017a). We will use the preferred methods to analyse ITS studies,
where possible, to make statistical comparisons of time trends
before and aMer the intervention. We will also consider techniques
of regression analysis with time trends before and aMer the
intervention, with adjustment for autocorrelation and any periodic
changes, or time series analysis using autoregressive integrated
moving average (ARIMA) models.
As there are a number of statistical techniques that can be used
depending on the characteristics of the data, decisions for the
methods used will be documented in the completed review, with
reference to the number of data points available and whether
autocorrelation is present. We will present the results for the
outcomes as changes along two dimensions: change in level and
change in slope (EPOC 2017a).
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Unit of analysis issues
Quantitative studies
We anticipate that studies will allocate individuals to one of two
intervention groups and a single measurement will be made for
each participant for each outcome. We do not expect to find cross-
over trials or studies that use repeated measures. If a unit-of-
analysis error is identified in the analysis of an included study, we
will assess if suFicient information is available to re-analyse the
results. We will contact study authors to obtain necessary data.
We will follow EPOC methods to perform analysis at the same
level as the allocation to avoid unit-of-analysis errors. If cluster-
randomised trials are identified, we will adjust the standard errors
or sample sizes using methods described by the EPOC analytic
methods group and the Cochrane Handbook (EPOC 2017a; Higgins
2019a). Based on methods described in the Cochrane Handbook we
plan to adjust cluster-randomised data by inflating standard errors
using a design eFect calculated with an intra-cluster correlation
coeFicient. If analogous studies are not available, we will use a
series of plausible values in a sensitivity analysis (see Sensitivity
analysis).
For NRSI, we plan to perform analysis at the same level as the
allocation to avoid unit-of-analysis errors. For cluster-randomised
trials, we plan to perform analysis adjusting for clustering to
avoid unit-of-analysis errors. We will review extracted results for
cluster trials to confirm analysis has been adjusted for clustering,
a reanalysis of the results will be performed (we will contact the
authors of such studies for the required data).
Dealing with missing data
Quantitative studies and qualitative studies
We plan to contact study authors to retrieve any missing
information. As part of Domain 3 of RoB 2, we will assess the
risk of missing data to define judgements of risk of bias.  If study
authors are unable to provide missing information, this will be
entered into the tool as 'no information' to contribute to the
algorithm to propose the judgement. The degree of 'missingness of
outcome data' will require  inference of  the true value, and will
be applied with reference to the Cochrane Handbook, review of
how the trial author has reported missing data, the proportion of




We intend to assess clinical heterogeneity by examining diFerences
in study characteristics in order to inform decisions regarding
the combination of study data. Heterogeneity will be defined as
clinical (variability in the participants, interventions and outcomes
studied); methodological (variability in study design and risk
of bias) and statistical (variability in the intervention eFects
being evaluated). The identification of clinical or methodological
heterogeneity, or both, among the studies will be used to describe
the intervention eFects being more diFerent from each other than
one would expect due to random error (chance) alone.
We will identify sources of clinical heterogeneity by constructing
tables to summarise studies in terms of participants, setting, type
of intervention, intervention delivery (e.g. group or individual,
number of visits/appointments) and outcomes examined. Where
studies are similar, we will conduct further investigations, initially
by visually reviewing the consistency of the results across studies
using graphical representations, e.g. forest plots (Deeks 2019). To
initially identify the heterogeneity/inconsistency of study results
we will use the Q statistic, separating the studies based on design.
We will assess statistical heterogeneity with the Chi2 test, to provide
evidence of variation in eFects, disregarding the eFect of chance.
As the Chi2 test is ineFective for analysing heterogeneity in studies
with only a small number of participants or trials, we plan to set the
P value at 0.10, and assess heterogeneity using the I2 statistic, which
will calculate the percentage of variability due to heterogeneity
outside of the eFect of chance (Deeks 2019).
We assume that some statistical heterogeneity is inevitable, and
hence, we will evaluate heterogeneity using the I2 statistic, using
the following thresholds of interpretation (Deeks 2019).
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity*.
• 50% to 90%: may represent substantial heterogeneity*.
• 75% to 100%: considerable heterogeneity*.
*The importance of the observed value of I2 depends on: 1) the
magnitude and direction of eFects, and 2) the strength of evidence
for heterogeneity (Deeks 2019). We will take into consideration
the size and direction of eFects, and the strength of evidence for
heterogeneity using the Chi2 test and the 95% CI for I2.
Where there is evidence for statistical heterogeneity, we will use
the strategies outlined in chapter 10 of the Cochrane Handbook
(Deeks 2019), to identify potential sources of heterogeneity
among the results of the studies. In particular, we will explore
diFerences in the characteristics of the studies or other factors
as possible explanations for heterogeneity in the results. We will
summarise any diFerences identified in the narrative summary.
We will investigate heterogeneity by using subgroup analyses to
explore whether the intervention eFects vary between populations
and intervention characteristics (see Subgroup analysis and
investigation of heterogeneity).
Non-randomised studies
It is anticipated that non-randomised studies will introduce greater
heterogeneity due to their methodological diversity, risks of bias
and extent of residual confounding (and the methods used to
control for confounding) (Reeves 2019). We plan to display any
variation in results with forest plots. Forests plots will be used
to display estimates of standard errors for each included study,
where possible using consistent eFect measures (if not available,
or calculable, then additional tables will be used to systematically
present results) (Reeves 2019).
Qualitative studies
For qualitative data, we intend to assess heterogeneity by
examining study diFerences (including methods of analysis
and types of participants) to allow appropriate synthesis/meta-
synthesis of data.
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Assessment of reporting biases
Quantitative studies
We plan to investigate outcome reporting bias using the ORBIT
matrix system (Kirkham 2010). We plan to assess publication bias
by identifying unpublished data, by carrying out a comprehensive
search of multiple sources and requesting any unpublished data
from study authors. If we are able to combine a suFicient number of
studies for analysis, we will assess funnel plots and look for small-
study eFects to establish the likelihood of publication bias (Higgins
2019b).
Qualitative studies
Dissemination bias is not included within the overall assessment
of GRADE-CERQual (Booth 2018a). Dissemination bias is presented
as a future component of the CERQual approach awaiting
methodological development, and is conceptualised as the
"systematic distortion of the phenomenon of interest due to
selective dissemination of qualitative studies or the findings of
qualitative studies" (Booth 2018a). We will report any changes
to protocol methods to take account of any methodological




We plan to perform data synthesis using Review Manager Web
(RevMan Web 2020). We plan to make comparisons between
separate comparisons for interventions and controls if data are
available. However, as previously noted, the use of the control
group might be a challenge; therefore, we plan to complete a
separate analysis for each intervention, e.g. intervention 1 versus
intervention 2.
If we do not identify substantial heterogeneity among the included
studies, we intend to use a fixed-eFect model to perform the meta-
analysis. If the statistical heterogeneity among the included studies
is substantial (indicated by an I2 value of more than 75%), we intend
to use a random-eFects model. If it is not possible to pool data, we
will provide clear reasons for this and report results narratively.
Qualitative studies
We plan to perform qualitative syntheses to help understand
how participation in preconception care interventions might
(or might not) improve perception/experience of maternal and
future infant health for WWE preparing for pregnancy and to
better understand the interventions' acceptability, usefulness and
barriers to uptake in a range of healthcare settings. The RETREAT
framework will be used to identify the most appropriate synthesis
method (Booth 2016b; Booth 2018b).   The RETREAT framework
is a conceptualisation of the important factors to be considered
in the selection of a method  of qualitative evidence synthesis.
The framework considers seven domains and within each domain
includes  questions concerning:  research question, epistemology,
time frame, resources, expertise, audience, and purpose and
type of data  (Booth 2016b; Booth 2018b).   The  final selection
of qualitative synthesis method will be deferred until the data
extraction is complete, and decision  rationale documented with
review methods (Booth 2016b; Flemming 2019; Noyes 2018b).
The type of data retrieved within the review findings will be
further categorised, in terms of quality/quantity (quantity will be
managed by application of a sampling frame, see Selection of
studies); context (thick/thin); theory (rich/poor); and the units of
analysis (Booth 2018b; Flemming 2019). The available time frame,
resources and review authors' expertise will be considered, as well
as the need for a pragmatic approach. Final consideration of the
purpose of this mixed-methods review to produce syntheses that
can subsequently be integrated within an intervention review will
take into account the recommendations of appropriate methods
including thematic synthesis, framework synthesis and meta-
ethnography (Flemming 2019; Noyes 2019a).
Mixed methods synthesis: combining quantitative and
qualitative data
We will use methods of synthesis to combine qualitative and
quantitative data as described in chapter 21 of the Cochrane
Handbook (Noyes 2019a), as well as the recommendations
outlined by the Cochrane Qualitative and Implementation Methods
Group (Harden 2018).
There are two main approaches to integrating qualitative and
quantitative data: sequential and convergent. The convergent
approach  involves qualitative and quantitative research being
collected and analysed at the same time in parallel, with the
integration occurring at three diFerent time points dependent on
the review objectives (Noyes 2018b; Noyes 2019b). We plan to use
a results-based convergent synthesis to support the origins of this
review update.
The choice of methods for this final synthesis will be dependent
on the number of studies and extracted evidence available, and
the quality of description within included studies (e.g. intervention
content, context, and study findings). The final synthesis method
will be selected from methods including;  for example, narrative,
tables, matrices or reanalysing evidence, to help to identify gaps in
the evidence (Noyes 2019b). If suFicient data are available we plan
to use juxtaposing synthesis methods to present findings in a matrix
with quantitative studies grouped according to preconception
interventions along one side of the matrix, with the themes
from qualitative evidence synthesis relating to the acceptability
and feasibility of the intervention components plotted along
the other side of the matrix to allow comparison (of match or
mismatch)  (Harden 2018). A juxtaposing synthesis using a matrix
will importantly help determine if the presence of acceptable/
feasible intervention components has an impact on the outcomes.
This approach can help us to understand why heterogeneity that
we may find in the quantitative analyses exists (Harden 2018).
We plan to use the results of this mixed-methods synthesis to
explore the convergence and divergence of results and we aim
to provide a narrative explanation of intervention eFectiveness.
Decisions made in the selection of mixed methods synthesis and
the application of the chosen methods will be fully documented
within the complete review.
Subgroup analysis and investigation of heterogeneity
Quantitative studies
Randomised studies
Where there are suFicient data, we will carry out subgroup analyses
based on the following factors that may cause the eFect of the
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preconception care intervention to vary. We will complete the sub-
group analysis on all primary outcomes.
• Location of intervention delivery (hospital or the community).
• Intervention content (e.g. changes of AED; provision of risk
information; commencement of folic acid).
• Delivery mode (individual (hospital or community clinic) or
group (hospital or community)).
• Length, frequency or intensity of intervention delivery.
• Delivery methods/personnel (e.g. multidisciplinary, individual
discipline).
• Participant ethnicity /Economic status (low-to-middle income,
or high-income countries)(as defined in the included studies).
• Country or location of study (Europe versus North America
versus Asia versus others).
• Study design
We will explore heterogeneity within these subgroups using the
Chi2 test and visual inspection of forest plots generated within
Review Manager Web (RevMan Web 2020). We will develop a
narrative summary for these subgroups and this will be supported
by harvest plots to help graphically illustrate the results. Risk of
bias will be presented as a traFic light plot on meta-analysis at the
results level.
Non-randomised studies
In addition to the above analyses, it is recognised that greater
heterogeneity is observed in NRSI; and where there are suFicient
data on intervention eFect estimates available, we will undertake




We will base our primary analyses on available data from all
included studies/results relevant to the comparison of interest.
However, in order to examine any eFects of methodological
decisions on the overall outcome, we will perform sensitivity
analyses provided there are suFicient numbers of studies. These
sensitivity analyses may include the following.
• Reanalysis of the data, excluding studies with results at high risk
of bias.
• Reanalysis of data, excluding studies judged to have  some
concerns of risk of bias for at least one domain of RoB 2.
• Reanalysis of the data, excluding studies with missing outcome
data.
Additional sensitivity analyses may be required if particular issues
related to the studies under review arise.
Qualitative studies
We will complete a qualitative ‘sensitivity analysis’, by exploring
the robustness of the synthesis and its vulnerability to
methodologically limited studies (Carroll 2013). This will involve
a reanalysis of the data following the exclusion of inadequately
reported studies. The reanalysis will question the impact of
exclusions upon the following.
• Themes generated within the initial synthesis.
• Richness ('thickness') of data within the synthesis.
These sensitivity analyses will be reported within the overall
confidence in synthesis findings.
Summary of findings and assessment of the certainty of the
evidence
Quantitative studies
We will create a ‘Summary of findings’ table for each comparison,
using GRADEpro GDT (GRADEpro GDT 2015). In these tables, we will
report the outcomes at post-intervention (Schünemann 2019a). We
will include all the primary preconception care  outcomes in the
'Summary of findings' tables.
The GRADE approach will be used to assess the certainty of
the evidence for each outcome, considering the risk of bias,
indirectness, inconsistency, imprecision of eFect estimates, and
risk of publication bias. For evidence from non-randomised studies
(and, rarely, randomised studies), assessments may be upgraded
through consideration of three further domains: eFect size; the
presence of plausible confounding that will change the eFect; and
dose-response gradient.
Two review authors (JW, CTS) will independently assess the
certainty of the evidence for each outcome, and assign ratings of
high, moderate, low or very low certainty, according to the presence
of the five criteria listed above and in line with methods described in
the Cochrane Handbook (Schünemann 2019a). We will take account
of the review objectives, and the recommendations in chapters
14 and 25 of the Cochrane Handbook (Schünemann 2019a; Sterne
2019a) when assessing the within-study risk of bias using GRADE
and ROBINS-I. We will use the Excel tool on the RoB 2 website to
record and manage the RoB 2 assessments that contribute into
GRADE, displaying traFic light plots for each result. We will describe
any patterns of bias seen across results and oFer our reasoned
interpretation.
We will report judgements in selecting the most appropriate
methods for presenting findings and will follow GRADE guidance
regarding presenting evidence from randomised trials and
evidence from non-randomised studies (Schünemann 2019b). In
keeping with Schünemann and colleagues (2019b), one 'Summary
of findings' table will be presented if the higher-certainty evidence
is from RCTs. If certainty ratings are the same between study
designs then separate 'Summary of findings' tables will be
presented for results from randomised trials and those from non-
randomised studies. If the results are consistent, then the overall
certainty assessment is that of the two bodies of evidence (typically,
findings from non-randomised studies are of lower certainty).
If the results are inconsistent, we will consider the bodies of
evidence from each study design and will downgrade further
for this inconsistency, and the final rating will be one category
lower (typically, non-randomised designs are graded as very-
low certainty), with all decisions reported within the final review
(Schünemann 2019b).
We plan to report the grading of the certainty of evidence in the
review results section for each outcome for which an assessment
is performed.  We will justify and document all assessments of
the certainty of the body of evidence and provide the rationale
for downgrading or upgrading the evidence, with reference to the
‘Summary of findings’ table as applicable.
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Qualitative studies
We will use the GRADE-CERQual approach to make a transparent
assessment of the degree of confidence in findings from the
synthesis of qualitative evidence (Noyes 2018b). The GRADE-
CERQual approach will be used to determine the confidence of
the evidence as an assessment of the extent to which the review
findings are a reasonable representation of the phenomenon of
interest, i.e. preconception interventions for WWE (Lewin 2018b;
Noyes 2019a). Confidence will be assessed for each review finding,
independently by two review authors (JW, AM). The assessment of
the confidence of the evidence will be based on the assessment of
four CERQual components/domains.
• Methodological limitations: the extent to which there are
problems in the design or conduct of the primary studies that
contributed evidence to a review finding.
• Coherence: the extent to which the review finding is well-
grounded in data from the contributing primary studies and
provides a convincing explanation for the patterns found in
these data.
• Adequacy of data: an overall determination of the degree of
richness and quantity of data supporting a review finding.
• Relevance: the extent to which the body of evidence from the
primary studies supporting a review finding is applicable to the
context (perspective or population, the phenomenon of interest,
setting) specified in the review question.
We will manage the results from qualitative synthesis, taking
account of the minimum criteria for fidelity to the GRADE-CERQual
approach (Lewin 2018a). We will record the transparency of quality
assessment and data synthesis using NVIVO 10 qualitative analysis
soMware to create a CERQual Summary of Qualitative Findings
table to display a structured summary of each study contributing
data to each finding (Lewin 2018b). The summary table will also
provide an assessment of confidence in the evidence as well as
an explanation of this assessment, based on the GRADE-CERQual
approach (Lewin 2018a).
Two review authors (JW; AM) will assign a level of confidence for
each component, as detailed below. By default, they will start with
'high confidence' and downgrade if there are concerns regarding
any of the CERQual components; they will provide a description of
the concerns influencing the decision (Lewin 2018b).
• High confidence: no or very minor concerns that are unlikely
to reduce confidence in the review finding as a reasonable
representation of the phenomenon of interest.
• Minor concerns: that may reduce confidence in the review
finding.
• Moderate concerns: that will probably reduce confidence in the
review finding.
• Serious concerns: that are very likely to reduce confidence in the
review finding.
Reflexivity
Reflexivity refers to the researchers' acknowledgement of potential
influence upon the findings, in relation to all aspects of the research
process including analysis and interpretation. Whilst seen as an
essential component of qualitative research quality, it has an
important role to play in quantitative research as a source of
bias. Within this mixed-methods review, it will be our intention
to incorporate reflexivity throughout, acknowledging the review
authors' prior standpoints, professional backgrounds and beliefs,
and the potential for these to influence judgements, review findings
and interpretations.
Involvement of patients and public
The review update and increased scope of the mixed methods
review protocol was the result of a wider consultation with
patients and public engagement. Members of Epilepsy Action, a UK
voluntary organisation, were surveyed concerning their experience
of preconception counselling for WWE in the UK. The protocol and
review will receive feedback from at least one consumer referee in
addition to a health professional as part of the Cochrane Epilepsy
editorial process.
Assessment of bias in conducting the review
We will conduct the review according to this published protocol and
justify any deviations from it in the 'DiFerences between protocol
and review' section of the systematic review.
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A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. MESH DESCRIPTOR Preconception Care EXPLODE ALL AND INSEGMENT
2. MESH DESCRIPTOR Pregnancy EXPLODE ALL AND INSEGMENT
3. MESH DESCRIPTOR Pregnant Women EXPLODE ALL AND INSEGMENT
4. pregnan* AND INSEGMENT
5. #2 OR #3 OR #4 AND INSEGMENT
6. MESH DESCRIPTOR Personal Narratives as Topic EXPLODE ALL AND INSEGMENT
7. (personal narratives):PT AND INSEGMENT
8. (narrativ* or biograph*) not "narrative review" AND INSEGMENT
9. #6 OR #7 OR #8 AND INSEGMENT
10. #5 AND #9 AND INSEGMENT
11. prepregnancy or "pre-pregnancy" or "pre pregnancy" AND INSEGMENT
12. (plan* NEAR3 pregnan*) OR (pregnan* NEAR3 plan*) AND INSEGMENT
13. (plan* NEAR3 conceive) OR (conceive NEAR3 plan*) AND INSEGMENT
14. (plan* NEAR3 conception) OR (conception NEAR3 plan*) AND INSEGMENT
15. preconception* or "pre-conception*" or "pre conception*" or periconception* or "peri-conception*" or "peri conception*" AND
INSEGMENT
16. reproductive health AND INSEGMENT
17. MeSH DESCRIPTOR Reproductive Health Explode All AND INSEGMENT
18. MeSH DESCRIPTOR Family Planning Services Explode All AND INSEGMENT
19. (plan* NEAR3 family) OR (family NEAR3 plan*) OR "planned parenthood" AND INSEGMENT
20. folic acid AND INSEGMENT
21. MeSH DESCRIPTOR Folic Acid Explode All AND INSEGMENT
22. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 AND INSEGMENT
23. MeSH DESCRIPTOR Counseling Explode All OR MESH DESCRIPTOR Health Promotion EXPLODE ALL OR MESH DESCRIPTOR Risk
Reduction Behavior EXPLODE ALL AND INSEGMENT
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24. counsel* or educat* or inform* or advice or advise AND INSEGMENT
25. #23 OR #24 AND INSEGMENT
26. #22 AND #25 AND INSEGMENT
27. #1 OR #10 OR #26 AND INSEGMENT
28. MESH DESCRIPTOR Preconception Care EXPLODE ALL AND CENTRAL:TARGET
29. MESH DESCRIPTOR Pregnancy EXPLODE ALL AND CENTRAL:TARGET
30. MESH DESCRIPTOR Pregnant Women EXPLODE ALL AND CENTRAL:TARGET
31. pregnan* AND CENTRAL:TARGET
32. #29 OR #30 OR #31 AND CENTRAL:TARGET
33. MESH DESCRIPTOR Personal Narratives as Topic EXPLODE ALL AND CENTRAL:TARGET
34. (personal narratives):PT AND CENTRAL:TARGET
35. (narrativ* or biograph*) not "narrative review" AND CENTRAL:TARGET
36. #33 OR #34 OR #35 AND CENTRAL:TARGET
37. #32 AND #36 AND CENTRAL:TARGET
38. prepregnancy or "pre-pregnancy" or "pre pregnancy" AND CENTRAL:TARGET
39. (plan* NEAR3 pregnan*) OR (pregnan* NEAR3 plan*) AND CENTRAL:TARGET
40. (plan* NEAR3 conceive) OR (conceive NEAR3 plan*) AND CENTRAL:TARGET
41. (plan* NEAR3 conception) OR (conception NEAR3 plan*) AND CENTRAL:TARGET
42. preconception* or "pre-conception*" or "pre conception*" or periconception* or "peri-conception*" or "peri conception*" AND
CENTRAL:TARGET
43. reproductive health AND CENTRAL:TARGET
44. MeSH DESCRIPTOR Reproductive Health Explode All AND CENTRAL:TARGET
45. MeSH DESCRIPTOR Family Planning Services Explode All AND CENTRAL:TARGET
46. (plan* NEAR3 family) OR (family NEAR3 plan*) OR "planned parenthood" AND CENTRAL:TARGET
47. folic acid AND CENTRAL:TARGET
48. MeSH DESCRIPTOR Folic Acid Explode All AND CENTRAL:TARGET
49. #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 AND CENTRAL:TARGET
50. MeSH DESCRIPTOR Counseling Explode All OR MESH DESCRIPTOR Health Promotion EXPLODE ALL OR MESH DESCRIPTOR Risk
Reduction Behavior EXPLODE ALL AND CENTRAL:TARGET
51. counsel* or educat* or inform* or advice or advise AND CENTRAL:TARGET
52. #50 OR #51 AND CENTRAL:TARGET
53. #49 AND #52 AND CENTRAL:TARGET
54. #28 OR #37 OR #53 AND CENTRAL:TARGET
55. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
56. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
57. epilep* OR seizure* OR convuls* AND CENTRAL:TARGET
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58. #55 OR #56 OR #57 AND CENTRAL:TARGET
59. #54 AND #58 AND CENTRAL:TARGET
60. #27 OR #59
Appendix 2. MEDLINE search strategy
1. exp Preconception Care/
2. exp Pregnancy/
3. exp Pregnant Women/
4. pregnan$.tw.
5. 2 or 3 or 4
6. exp personal narratives as topic/
7. personal narratives.pt.
8. ((narrativ$ or biograph$) not "narrative review").tw.
9. 6 or 7 or 8
10. 5 and 9
11. (prepregnancy or "pre-pregnancy" or "pre pregnancy").tw.
12. (plan$ adj3 pregnan$).ti,ab.
13. (plan$ adj3 conceive).ti,ab.
14. (plan$ adj3 conception).ti,ab.
15. (preconception$ or "pre-conception$" or "pre conception$" or periconception$ or "peri-conception$" or "peri conception$").tw.
16. reproductive health.mp. or exp Reproductive Health/
17. exp Family Planning Services/
18. ((family adj3 plan$) or "planned parenthood").ti,ab.
19. folic acid.mp. or exp Folic Acid/
20. or/11-19
21. exp Counseling/ or exp Health Promotion/ or exp Risk Reduction Behavior/
22. (counsel$ or educat$ or inform$ or advice or advise).tw.
23. 21 or 22
24. 20 and 23
25. exp Epilepsy/
26. exp Seizures/
27. (epilep$ or seizure$ or convuls$).tw.
28. 25 or 26 or 27
29. exp *Pre-Eclampsia/ or exp *Eclampsia/
30. 28 not 29
31. 1 or 10 or 24
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32. 30 and 31
33. remove duplicates from 32
Appendix 3. SCOPUS search strategy
((TITLE-ABS(pregnan* AND (narrativ* or biograph*) AND NOT "narrative review")) OR (((TITLE-ABS-KEY(prepregnancy OR "pre-pregnancy"
OR "pre pregnancy" OR preconception* OR "pre-conception*" OR "pre conception*" OR periconception* OR "peri-conception*" OR "peri
conception*")) OR (TITLE-ABS-KEY("family planning" OR "reproductive health" OR "planned parenthood" OR "folic acid"))) AND (TITLE-
ABS-KEY(counsel* OR educat* OR inform* OR advise OR advice)))) AND ((TITLE-ABS-KEY(epilep* OR "infantile spasm" OR "ring chromosome
20" OR "R20" OR "myoclonic encephalopathy" OR "pyridoxine dependency") OR (TITLE-ABS-KEY(syndrome) W/2 (aicardi OR angelman OR
doose OR dravet OR janz OR jeavons OR "landau kleFner" OR "lennox gastaut" OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR
"sturge weber" OR tassinari OR "unverricht lundborg" OR west)) OR TITLE(seizure OR convuls*) OR (TITLE-ABS-KEY(lafora*) W/4 (disease OR
epilep*) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine)))) AND NOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia)))
AND NOT INDEX(medline)
Plus forward citation searches for:
(AUTHOR-NAME(Weckesser) AND TITLE("Re-working biographies")) OR (AUTHOR-NAME(Weckesser) AND TITLE("women living with
epilepsy")) OR (AUTHOR-NAME(Pashley) AND TITLE("The safety of anti-epileptic drug regimens")) OR (AUTHOR-NAME(Thompson) AND
TITLE("Chronic illness, reproductive health and moral work")) OR (AUTHOR-NAME(Wallace) AND TITLE("Quality of epilepsy treatment and
services"))
Appendix 4. CINAHL Plus search strategy
S13 S9 AND S12
S12 S10 OR S11
S11 MM ("Epilepsy+") OR (MM "Seizures")
S10 epilep* OR seizure*
S9 S1 OR S2 OR S8
S8 S6 AND S7
S7 counsel* OR educat* OR inform* OR advise OR advice
S6 S3 OR S4 OR S5
S5 prepregnancy OR "pre-pregnancy" OR "pre pregnancy" OR preconception* OR "pre-conception*" OR "pre conception*" OR
periconception* OR "peri-conception*" OR "peri conception*"
S4 family planning OR reproductive health OR planned parenthood OR folic acid
S3 (MM "Family Planning") OR (MM "Reproductive Health") OR (MM "Folic Acid")
S2 MM "Prepregnancy Care"
S1 pregnan* AND ( (narrativ* or biograph*) ) NOT "narrative review"
Appendix 5. PsycINFO Search strategy
S13 S9 AND S12
S12 S10 OR S11
S11 MM ("Epilepsy+") OR (MM "Seizures")
S10 epilep* OR seizure*
S9 S1 OR S2 OR S8
S8 S6 AND S7
S7 counsel* OR educat* OR inform* OR advise OR advice
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S6 S3 OR S4 OR S5
S5 prepregnancy OR "pre-pregnancy" OR "pre pregnancy" OR preconception* OR "pre-conception*" OR "pre conception*" OR
periconception* OR "peri-conception*" OR "peri conception*"
S4 family planning OR reproductive health OR planned parenthood OR folic acid
S3 (MM "Family Planning") OR (MM "Reproductive Health") OR (MM "Folic Acid")
S2 MM "Prepregnancy Care"
S1 pregnan* AND ( (narrativ* or biograph*) ) NOT "narrative review"
Appendix 6. CASP 2013
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 31.05.13 (CASP 2018)
We will assess the methodological limitations for each included qualitative study using an the Critical Appraisal Skills Programme (CASP)
quality assessment tool and record results of the following ten questions.
1. Was there a clear statement of the aims of the research? #Yes #Can’t tell #No
Consider:
• What is the goal of the research?
• Why is it important?
• Its relevance
2. Is a qualitative methodology appropriate? #Yes #Can’t tell #No
Consider:
• If the research seeks to interpret or illuminate the actions and/or subjective experiences of research participants
• Is qualitative research the right methodology for addressing the research goal?
3. Was the research design appropriate to address the aims of the research? #Yes #Can’t tell #No
Consider:
• If the researcher has justified the research design (e.g. have they discussed how they decided which method to use?)
4. Was the recruitment strategy appropriate to the aims of the research? #Yes #Can’t tell #No
Consider:
• If the researcher has explained how the participants were selected
• If they explained why the participants they selected were the most appropriate to provide access to the type of knowledge sought by
the study
• If there are any discussions around recruitment (e.g. why some people chose not to take part)
5. Were the data collected in a way that addressed the research issue? #Yes #Can’t tell #No
Consider:
• If the setting for data collection was justified
• If it is clear how data were collected (e.g. focus group, semi-structured interview, etc.)
• If the researcher has justified the methods chosen
• If the researcher has made the methods explicit (e.g. for interview method, is there an indication of how interviews were conducted,
or did they use a topic guide?)
• If methods were modified during the study. If so, has the researcher explained how and why?
• If the form of data is clear (e.g. tape recordings, video material, notes, etc.)
• If the researcher has discussed saturation of data
6. Has the relationship between researcher and participants been adequately considered? #Yes #Can’t tell #No
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Consider:
• If the researcher critically examined their own role, potential bias and influence during:
* Formulation of the research questions
* Data collection, including sample recruitment and choice of location
• How the researcher responded to events during the study and whether they considered the implications of any changes in the research
design
7. Have ethical issues been taken into consideration? #Yes #Can’t tell #No
Consider:
• If there are suFicient details of how the research was explained to participants for the reader to assess whether ethical standards were
maintained
• If the researcher has discussed issues raised by the study (e.g. issues around informed consent or confidentiality or how they have
handled the eFects of the study on the participants during and aMer the study)
• If approval has been sought from the ethics committee
8. Was the data analysis suBiciently rigorous? #Yes #Can’t tell #No
Consider:
• If there is an in-depth description of the analysis process
• If thematic analysis is used. If so, is it clear how the categories/themes were derived from the data?
• Whether the researcher explains how the data presented were selected from the original sample to demonstrate the analysis process
• If suFicient data are presented to support the findings
• To what extent contradictory data are taken into account
• Whether the researcher critically examined their own role, potential bias and influence during analysis and selection of data for
presentation
9. Is there a clear statement of findings? #Yes #Can’t tell #No
Consider:
• If the findings are explicit
• If there is adequate discussion of the evidence both for and against the researcher’s arguments
• If the researcher has discussed the credibility of their findings (e.g. triangulation, respondent validation, more than one analyst)
• If the findings are discussed in relation to the original research question
10. How valuable is the research?
Consider:
• If the researcher discusses the contribution the study makes to existing knowledge or understanding e.g. do they consider the findings
in relation to current practice or policy, or relevant research-based literature?
• If they identify new areas where research is necessary
• If the researchers have discussed whether or how the findings can be transferred to other populations or considered other ways the
research may be used
W H A T ' S   N E W
 
Date Event Description
3 December 2020 New citation required and major
changes
Since the previous protocol published in 2014 (Winterbottom
2014b), the review team have updated the methodology to ad-
here to the guidelines for a Cochrane mixed methods review.
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